RxDoctor Payments Data

Janice Langer, MD

Family Medicine · Williamsburg, VANPI 1669466520

Payments from drug & device makers

$941in general payments, 2019–2025

Across 17 payments — averaging $55.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$259
  • Lilly USA, LLC$230
  • GSK$142
  • Scpharmaceuticals Inc.$132
  • Amgen$112
  • Abbott$42
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$259
Lilly USA, LLC2$230
GSK2$142
Scpharmaceuticals Inc.1$132
Amgen7$112
Abbott2$42
Exact Sciences1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$941 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$297,624
Medicare patients
689
Services billed
3,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$144,882
JardianceEmpagliflozin103$114,829
JanuviaSitagliptin Phosphate50$63,765
MounjaroTirzepatide34$36,456
XareltoRivaroxaban24$31,467
ProliaDenosumab11$19,641
Breo ElliptaFluticasone/Vilanterol16$7,913
Atorvastatin Calcium788$7,356
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,764
Repatha SureclickEvolocumab12$6,503
SynthroidLevothyroxine Sodium98$5,039
Losartan Potassium401$4,366
Levothyroxine Sodium401$4,278
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,060
Metoprolol Succinate242$3,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$230$36,45634 claims
AmgenProlia$112$19,64111 claims
GSKBreo Ellipta$142$7,91316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →